# Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

> **NCT02382640** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Febuxostat XR
- **DRUG:** Maalox Advance Regular Strength liquid

## Key facts

- **NCT ID:** NCT02382640
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382640, "Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT02382640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*